Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pooled Analysis of Individual Subjects' Data After Combining the Data From the Bioequivalence Studies Conducted for Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals (Test, T) vs ADVAIR DISKUS® 250/50 mcg Inhalation Powder/GSK (Reference, R)

NCT04790838 is registered in ClinicalTrials.gov with Respirent Pharmaceuticals Co Ltd. as lead sponsor.

NCT NCT04790838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04790838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pooled Analysis of Individual Subjects' Data After Combining the Data From the Bioequivalence Studies Conducted for Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals (Test, T) vs ADVAIR DISKUS® 250/50 mcg Inhalation Powder/GSK (Reference, R)
Lead sponsor
Respirent Pharmaceuticals Co Ltd.
Phase
Observational
Overall status
Completed
Start date
June 2, 2019
Completion date
December 31, 2020
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma